Open Access
Ann Toxicol Anal
Volume 20, Number 4, 2008
Page(s) 223 - 226
Published online 25 April 2009
  1. Foulds J. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract. 2006; 60: 571-576. [CrossRef] [PubMed] [Google Scholar]
  2. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst. 2007; Rev. 24: CD006103. [Google Scholar]
  3. Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB Jr, Gong J, Williams KE, Reeves KR. Varenicline versus transdermal nicotine patch for smoking cessation: Results from a randomised open-label trial. Thorax. 2008; 63: 717-724. [CrossRef] [PubMed] [Google Scholar]
  4. Tonstad S. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist. J Cardiovasc Nurs. 2006; 21: 433-436. [CrossRef] [PubMed] [Google Scholar]
  5. Lam S, Patel PN. Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation. Cardiol Rev. 2007; 15: 154-161. [CrossRef] [PubMed] [Google Scholar]
  6. Williams KE, Reeves KR, Billing CB Jr, Pennington AM, Gong J. A double-blind study evaluating the long-term safety for smoking cessation. Curr Med Res Opin. 2007; 23: 793-801. [CrossRef] [PubMed] [Google Scholar]
  7. Kohen I, Kremen N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry. 2007; 164: 1269-1270. [CrossRef] [Google Scholar]
  8. Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry. 2007; 164: 1269. [CrossRef] [PubMed] [Google Scholar]
  9. No authors listed. New smoking cessation preparations unsuitable in mental disorders. Lakartidningen. 2007; 104: 1825. [PubMed] [Google Scholar]
  10. Popkin MK. Exacerbation of recurrent depression as a result of treatment with varenicline. Am J Psychiatry. 2008; 165: 774. [CrossRef] [PubMed] [Google Scholar]
  11. Obach RS, Reed-Hagen AE, Krueger SS, Obach BJ, O'Connell TN, Zandi KS, Miller S, Coe JW. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos. 2006; 34: 121-130. [CrossRef] [PubMed] [Google Scholar]
  12. Faessel HM, Gibbs MA, Clark DJ, Rohrbacher K, Stolar M, Burstein AH. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers. J Clin Pharmacol. 2006; 46: 1439-1448. [CrossRef] [PubMed] [Google Scholar]